Download PDF
Am J Perinatol 2017; 34(12): 1227-1233
DOI: 10.1055/s-0037-1603344
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Antenatal Exposure to Magnesium Sulfate and Spontaneous Intestinal Perforation and Necrotizing Enterocolitis in Extremely Preterm Neonates

Mohamed Shalabi
1   Department of Pediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada
,
Adel Mohamed
1   Department of Pediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada
,
Brigitte Lemyre
2   Department of Paediatrics, University of Ottawa, Ottawa, Ontario, Canada
,
Khalid Aziz
3   Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
,
Daniel Faucher
4   Department of Pediatrics, McGill University, Montreal, Quebec, Canada
,
Prakesh S. Shah
1   Department of Pediatrics, Mount Sinai Hospital, Toronto, Ontario, Canada
5   Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
,
for the Canadian Neonatal Network Investigators › Author Affiliations
Further Information

Publication History

30 November 2016

08 April 2017

Publication Date:
11 May 2017 (online)

    Permissions and Reprints

Abstract

Background There have been recent concerns regarding the higher rates of spontaneous intestinal perforation (SIP) in preterm infants that have been exposed to intrapartum magnesium sulfate (MgSO4).

Objective To assess the association between intrapartum MgSO4 exposure and necrotizing enterocolitis (NEC) and/or SIP in extremely preterm neonates.

Design A retrospective cohort study was conducted using data from the Canadian Neonatal Network database. Infants born at < 28 weeks' gestation admitted to neonatal units in Canada between 2011 and 2014 were divided into two groups: those exposed antenatally to MgSO4 and those unexposed. Stratified analyses for infants born between 22 and 25 weeks' gestation and those born between 26 and 27 weeks' gestation were conducted. The primary outcome was intestinal injury, identified as either NEC or SIP. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were calculated using multivariable logistic regression.

Results We compared 2,300 unexposed infants with 2,055 exposed infants. There was no difference in the odds of NEC (9.88% exposed vs. 9.59% unexposed; aOR: 0.92; 95% CI: 0.75–1.14) or SIP (3.4% exposed vs. 3.39% unexposed; aOR: 1.05; 95% CI: 0.75–1.48) between the two groups.

Conclusion Antenatal exposure to MgSO4 was not associated with NEC or SIP in extremely preterm infants.

Keywords

magnesium sulfate - spontaneous intestinal perforation - necrotizing enterocolitis - preterm infants

Canadian Neonatal Network Investigators

Prakesh S Shah, MD, MSc (Director of the Canadian Neonatal Network, and site investigator), Mount Sinai Hospital, Toronto, Ontario; Adele Harrison, MD, MBChB, Victoria General Hospital, Victoria, British Columbia; Anne Synnes, MDCM, MHSC, and Joseph Ting, MD, B.C. Women's Hospital and Health Centre, Vancouver, British Columbia; Zenon Cieslak, MD, Royal Columbian Hospital, New Westminster, British Columbia; Rebecca Sherlock, MD, Surrey Memorial Hospital, Surrey, British Columbia; Wendy Yee, MD, Foothills Medical Centre, Calgary, Alberta; Khalid Aziz, MBBS, MA, MEd, and Jennifer Toye, MD, Royal Alexandra Hospital, Edmonton, Alberta; Carlos Fajardo, MD, Alberta Children's Hospital, Calgary, Alberta; Zarin Kalapesi, MD, Regina General Hospital, Regina, Saskatchewan; Koravangattu Sankaran, MD, MBBS, and Sibasis Daspal, MD, Royal University Hospital, Saskatoon, Saskatchewan; Mary Seshia, MBChB, Winnipeg Health Sciences Centre, Winnipeg, Manitoba; Ruben Alvaro, MD, St. Boniface General Hospital, Winnipeg, Manitoba; Amit Mukerji, MD, Hamilton Health Sciences Centre, Hamilton, Ontario; Orlando Da Silva, MD, MSc, London Health Sciences Centre, London, Ontario; Chuks Nwaesei, MD, Windsor Regional Hospital, Windsor, Ontario; Kyong-Soon Lee, MD, MSc, Hospital for Sick Children, Toronto, Ontario; Michael Dunn, MD, Sunnybrook Health Sciences Centre, Toronto, Ontario; Brigitte Lemyre, MD, Children's Hospital of Eastern Ontario and Ottawa General Hospital, Ottawa, Ontario; Kimberly Dow, MD, Kingston General Hospital, Kingston, Ontario; Ermelinda Pelausa, MD, Jewish General Hospital, Montréal, Québec; Keith Barrington, MBChB, Hôpital Sainte-Justine, Montréal, Québec; Christine Drolet, MD, and Bruno Piedboeuf, MD, Centre Hospitalier Universitaire de Québec, Sainte Foy Québec; Martine Claveau, MSc, LLM, NNP, and Marc Beltempo, MD, McGill University Health Centre, Montréal, Québec; Valerie Bertelle, MD, and Edith Masse, MD, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec; Roderick Canning, MD, Moncton Hospital, Moncton, New Brunswick; Hala Makary, MD, Dr. Everett Chalmers Hospital, Fredericton, New Brunswick; Cecil Ojah, MBBS, and Luis Monterrosa, MD, Saint John Regional Hospital, Saint John, New Brunswick; Akhil Deshpandey, MBBS, MRCPI, Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland; Jehier Afifi, MB BCh, MSc, IWK Health Centre, Halifax, Nova Scotia; Andrzej Kajetanowicz, MD, Cape Breton Regional Hospital, Sydney, Nova Scotia; Shoo K Lee, MBBS, PhD (Chairman of the Canadian Neonatal Network), Mount Sinai Hospital, Toronto, Ontario.


 

  • References

  • 1 Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105 (03) 300-303
    CrossrefPubMedGoogle Scholar
  • 2 Scardo JA, Hogg BB, Newman RB. Favorable hemodynamic effects of magnesium sulfate in preeclampsia. Am J Obstet Gynecol 1995; 173 (04) 1249-1253
    CrossrefPubMedGoogle Scholar
  • 3 Duley L. ; Eclampsia Trial Collaborative Group. Magnesium sulphate in eclampsia. Lancet 1998; 352 (9121): 67-68
    CrossrefPubMedGoogle Scholar
  • 4 Belfort MA, Moise Jr KJ. Effect of magnesium sulfate on maternal brain blood flow in preeclampsia: a randomized, placebo-controlled study. Am J Obstet Gynecol 1992; 167 (03) 661-666
    CrossrefPubMedGoogle Scholar
  • 5 Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995; 95 (02) 263-269
    Google Scholar
  • 6 Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996; 276 (22) 1805-1810
    CrossrefPubMedGoogle Scholar
  • 7 Crowther CA, Hiller JE, Doyle LW, Haslam RR. ; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290 (20) 2669-2676
    CrossrefPubMedGoogle Scholar
  • 8 Rouse DJ, Hirtz DG, Thom E. , et al; Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008; 359 (09) 895-905
    CrossrefPubMedGoogle Scholar
  • 9 Marret S, Marpeau L, Follet-Bouhamed C. , et al; le groupe PREMAG. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial [in French]. Gynecol Obstet Fertil 2008; 36 (03) 278-288
    CrossrefPubMedGoogle Scholar
  • 10 Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009; (01) CD004661 . Doi: 10.1002/14651858.CD004661.pub3
    PubMedGoogle Scholar
  • 11 Costantine MM, Weiner SJ. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. Obstet Gynecol 2009; 114 (2 Pt 1): 354-364
    CrossrefPubMedGoogle Scholar
  • 12 Doyle LW, Anderson PJ, Haslam R, Lee KJ, Crowther C. ; Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Study Group. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. JAMA 2014; 312 (11) 1105-1113
    CrossrefPubMedGoogle Scholar
  • 13 Chollat C, Enser M, Houivet E. , et al. School-age outcomes following a randomized controlled trial of magnesium sulfate for neuroprotection of preterm infants. J Pediatr 2014; 165 (02) 398-400.e3
    CrossrefPubMedGoogle Scholar
  • 14 Weisz DE, Shivananda S, Asztalos E. , et al; Canadian Neonatal Network. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation. Arch Dis Child Fetal Neonatal Ed 2015; 100 (01) F59-F65
    CrossrefPubMedGoogle Scholar
  • 15 Rattray BN, Kraus DM, Drinker LR, Goldberg RN, Tanaka DT, Cotten CM. Antenatal magnesium sulfate and spontaneous intestinal perforation in infants less than 25 weeks gestation. J Perinatol 2014; 34 (11) 819-822
    CrossrefPubMedGoogle Scholar
  • 16 Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000; 38 (04) 305-314
    CrossrefPubMedGoogle Scholar
  • 17 Havranek T, Ashmeade TL, Afanador M, Carver JD. Effects of maternal magnesium sulfate administration on intestinal blood flow velocity in preterm neonates. Neonatology 2011; 100 (01) 44-49
    CrossrefPubMedGoogle Scholar
  • 18 Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986; 33 (01) 179-201
    CrossrefPubMedGoogle Scholar
  • 19 Gordon PV, Swanson JR, Attridge JT, Clark R. Emerging trends in acquired neonatal intestinal disease: is it time to abandon Bell's criteria?. J Perinatol 2007; 27 (11) 661-671
    CrossrefPubMedGoogle Scholar
  • 20 Shah J, Singhal N, da Silva O. , et al; Canadian Neonatal Network. Intestinal perforation in very preterm neonates: risk factors and outcomes. J Perinatol 2015; 35 (08) 595-600
    Google Scholar
  • 21 Kamyar M, Clark EA, Yoder BA, Varner MW, Manuck TA. Antenatal magnesium sulfate, necrotizing enterocolitis, and death among neonates < 28 weeks gestation. AJP Rep 2016; 6 (01) e148-e154
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Zeng X, Xue Y, Tian Q, Sun R, An R. Effects and safety of magnesium sulfate on neuroprotection: a meta-analysis based on PRISMA guidelines. Medicine (Baltimore) 2016; 95 (01) e2451 . Doi: 10.1097/MD.0000000000002451
    CrossrefPubMedGoogle Scholar
  • 23 Gursoy T, Imamoglu EY, Ovali F, Karatekin G. Effects of antenatal magnesium exposure on intestinal blood flow and outcome in preterm neonates. Am J Perinatol 2015; 32 (11) 1064-1069
    Article in Thieme ConnectPubMedGoogle Scholar